Pernix Therapeutics Holdings (PTX): Price Target and June Short Interest Disclosure

Pernix Therapeutics Holdings (PTX) : 2 Wall Street analysts covering Pernix Therapeutics Holdings (PTX) believe that the average level the stock could reach for the short term is $6.5. The maximum price target given is $10 and the minimum target for short term is around $3, hence the standard deviation is calculated at $4.95.

Pernix Therapeutics Holdings (PTX), According to the latest information the short interest in Pernix Therapeutics Holdings, Inc. plummeted by 27.1% or 2,186,743 shares. The final shorts are 11.9% of the total floated shares. The positions dropped from 8,078,760 shares on June 15,2016 to 5,892,017 on June 30,2016. According to the per-day average trading of 4,978,030 shares, the days to cover are 1. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.


Pernix Therapeutics Holdings (NASDAQ:PTX): On Thursdays trading session , Opening price of the stock was $0.55 with an intraday high of $0.6. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.54. However, the stock managed to close at $0.5779, a loss of 0.40% for the day. On the previous day, the stock had closed at $0.5802. The total traded volume of the day was 2,986,895 shares.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.